Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose general physical health and ability to carry out daily activities is rated at a high level, based on a standard cancer performance scale (a score of 0 or 1 out of 5)
- People who have been diagnosed with smouldering multiple myeloma (a pre-cancer blood condition) according to specific international diagnostic guidelines
- People whose smouldering multiple myeloma is considered high-risk, based on at least one of the risk-scoring methods specified in the trial protocol
Who may not be able to join:
- People who have already developed signs that their plasma cell condition has progressed to active myeloma, as defined in the trial protocol
- People who have a diagnosis of certain related blood or plasma cell conditions, including systemic light chain amyloidosis, Waldenström macroglobulinemia, plasma cell leukaemia, or soft tissue plasmacytoma
- People with a history of certain conditions affecting the brain or nervous system, including neurodegenerative diseases, progressive multifocal leukoencephalopathy, or movement disorders of the central nervous system
- People who have had a seizure within the 12 months before joining the trial
- People who have previously received any approved or investigational treatment aimed at a plasma cell disorder — including chemotherapy, radiotherapy, immunomodulatory drugs, proteasome inhibitors, or anti-CD38 antibody treatments — or who are currently receiving other treatments (such as certain monoclonal antibodies) that may interfere with the trial (confirm with trial site for full details)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinical Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) criteria; Biochemical PFS per IMWG criteria
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.